ArticleAngiogenesis2025
A novel quantitative angiogenesis assay based on visualized vascular organoid.
Article in Angiogenesis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Angiogenesis: a research field in full bloom.Angiogenesis · 2026Article
- Lung-targeted hepatocyte growth factor mRNA restores alveolar structure in experimental emphysema.The European respiratory journal · 2026Article
- Chinese expert consensus on the clinical application of stromal vascular fraction combined with bone marrow flushing for osteonecrosis of the femoral head.Journal of orthopaedic translation · 2026Review
- Generation of synthetic vascular organoids via orthogonal programming of human pluripotent stem cells.Cell regeneration (London, England) · 2026Article
- Recent advances and expanding applications of organoid models in unveiling drug ADME profiles.Journal of pharmaceutical analysis · 2026Review
- Fluorescently engineered KRAS-mutant organoids as versatile tools for in vitro and in vivo cancer modeling.Biochemistry and biophysics reports · 2026Article
- Mono(2-Ethylhexyl) Phthalate Induces Inflammatory and Angiogenic Alterations Mediated by the PI3K/AKT Pathway in HTR-8/SVneo Trophoblastic Cells.Environmental toxicology · 2026Article
- Murine vascular organoids are responsive and adaptable 3D systems with cellular heterogeneity and dynamic plasticity.Science advances · 2025Article
- Age-Related Macular Degeneration: Cellular and Molecular Signaling Mechanisms.International journal of molecular sciences · 2025Review
- Towards advanced regenerative therapeutics to tackle cardio-cerebrovascular diseases.American heart journal plus : cardiology research and practice · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Angiogenesis describes the sprouting of blood vessels from existing vasculatures and it plays a pivotal role in disease progress such as diabetes, age-related macular degeneration and cancer. However, the most widely used anti-angiogenic agents targeting vascular endothelial growth factor (VEGF) pathway still lacked of specificity and therapeutic efficacy. To establish a method suitable for high-throughput drug screening and faithfully recapitulate the feature of in vivo angiogenesis, we generated a PECAM1-mRuby3-secNluc; ACTA2-EGFP dual reporter human pluripotent stem cell (hPSC) line and utilizing the cell line to establish a visualized and quantifiable in vitro angiogenesis model with stem cell-derived vascular organoid. Using this method, we evaluated the anti-angiogenic effect of VEGFR inhibitor and efficiently identified several potential candidates of pro- and anti-angiogenic therapy via bioluminescence-based quantification. Overall, our study provides a valuable platform for in vitro drug screenings.
Indexed as
Identifiers
39751990What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.